MET and hepatocellular carcinoma: MET gene amplification, which leads to a constitutively active receptor due to overexpression, has been identified in patients with gastric cancers, lung tumors, renal cell carcinomas, hepatocellular carcinomas, ovarian tumors, melanomas, and triple-negative breast cancer (TNBC) [21].